



MEGACE (MEGESTROL ACETATE)

Summary

Megace is used as a treatment for weight loss. It can improve appetite and help people gain weight. Most of the weight is gained as fat, not muscle. A single dose of 10-20 ml liquid, containing 400-800 mg Megace, is taken daily.

What is Megace?

Megestrol acetate, sold under the brand name Megace, is a synthetic version of the hormone *progesterone*. It has been available for many years as a palliative treatment for some advanced cancers. About ten years ago, researchers observed that women receiving Megace as a treatment for breast cancer gained weight. A number of clinical trials were run and Megace was subsequently approved to promote appetite and weight gain in people with cancer or AIDS-related weight loss.

How is it used?

Megace may be used to treat unexplained weight loss or loss of appetite in HIV-positive people, although it is not clear exactly how this drug works.

Von Roenn and Oster each conducted large placebo-controlled studies of Megace in HIV-positive men who had lost at least 10% of their normal body weight. After 12 weeks of study, both trials showed that those who had received 800 mg Megace daily gained weight (an average of 3.54 kg in Von Roenn's study and 4.16 kg in Oster's). It is important to note that most of the weight gained was fat, rather than lean body mass (muscle). In addition to the increase in weight, participants

who received Megace reported an improved sense of well-being.

Dosage

The recommended daily dose of Megace is 400 to 800 mg in liquid suspension. Megace is available in tablets but it would take 20 pills a day to get the recommended dose.

Side effects

The most common side effects reported in clinical trials of Megace were diarrhea, rash, high blood pressure, insomnia, and nausea.

Megace is a hormonal drug that may affect men and women differently. Women may experience changes in their menstrual periods, including unpredictable bleeding. Men may experience impotence (erectile dysfunction)

Drug interactions

Interactions of other drugs with Megace have not been studied. Rifampin may decrease blood levels of Megace, thus reducing its effects.

Availability

Megace is a prescription drug approved for sale in Canada.



Credits

Author: Deirdre Maclean, B. Toulouse

Created: December 1998

Design: Renata Lipovitch

References

Engelson ES, Pi-Sunyer FX, Kotler DP. Effects of megestrol acetate therapy on body composition and circulating testosterone concentrations in patients with AIDS. *AIDS* 1995;9(9):1107-8.

Gillis MC. CPS: Compendium of Pharmaceuticals and Specialties. 33rd edition. Ottawa: Canadian Pharmaceutical Association, 1998.

Graham KK, Mikolich DJ, Fisher AE, *et al.* Pharmacologic evaluation of megestrol acetate oral suspension in cachectic AIDS patients. *Journal of Acquired Immune Deficiency Syndromes* 1994;7:5880-586.

Oster MH, Enders SR, Samuels SJ, *et al.* Megestrol acetate in patients with AIDS and cachexia. *Annals of Internal Medicine* 1994;121:400-408.

Tchekmedyan NS, Hickman M, Heber D. Treatment of anorexia and weight loss with megestrol acetate in patients with cancer or acquired immunodeficiency syndrome. *Seminars in Oncology* 1991;18(1) Suppl 2:35-42.

Von Roenn JH, Armstrong D, Kotler DP, *et al.* Megestrol acetate in patients with AIDS-related cachexia. *Annals of Internal Medicine* 1994;121:393-399.

Tobin, MA, Chow FJ, Bowmer MI, Bally GA. *A Comprehensive Guide for the Care of Persons with HIV Disease: Module 1. Revised edition.* Mississauga: The College of Family Physicians of Canada, 1996.

Disclaimer

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV-related illness and the treatments in question.

The Canadian AIDS Treatment Information Exchange (CATIE) in good faith provides information resources to help people living with HIV/AIDS who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.

We do not guarantee the accuracy or completeness of any information accessed through or published or provided by CATIE. Users relying on this information do so entirely at their own risk. Neither CATIE nor Health Canada nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. The views expressed herein or in any article or publication accessed or published or provided by CATIE are solely those of the authors and do not reflect the policies or opinions of CATIE or the official policy of the Minister of Health Canada.

Permission to reproduce

This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: *This information was provided by the Canadian AIDS Treatment Information Exchange (CATIE). For more information, contact CATIE at 1.800.263.1638.*



Contact CATIE

by telephone

1.800.263.1638

416.203.7122

by fax

416.203.8284

by e-mail

info@catie.ca

on the Web

<http://www.catie.ca>

by mail

505-555 Richmond Street West

Box 1104

Toronto, Ontario

M5V 3B1

Canada



Funding has been provided by Health Canada,
under the Canadian Strategy on HIV/AIDS.

